InvestorsObserver
×
News Home

Supernus Pharm Up 0.86% To $30.96 After Earnings Miss

Wednesday, February 28, 2024 01:28 PM | InvestorsObserver Analysts

Mentioned in this article

Supernus Pharm Up 0.86% To $30.96 After Earnings Miss

Supernus Pharm (SUPN) said after close Tuesday that it earned $0.39 per share in quarter four 2023. The company reported earnings on an adjusted basis, so it may not be directly comparable to analyst estimates or prior periods.

On the revenue line, the company reported $164.3 million, beating estimates by $9.3 million.

In the same quarter a year ago, the company earned $0.43 per share on revenue of $167.3 million.

The stock is up 0.86% to $30.96 after the report.

Supernus Pharm's profit margins took a hit as earnings fell at a faster pace than revenues.

Wall Street Analysts had an average rating of Strong Buy on the stock prior to the report.

InvestorsObserver gives the stock a Bullish Sentiment score at the moment based on recent trading.

Supernus Pharm has performed a little below average during the past few months. Before the report, Supernus Pharm received a Long-Term Technical Rank by InvestorsObserver of 43, putting it in the bottom half of stocks. The firm set a 52-week low on October 27, 2023 at $21.99 and set a 52-week high on March 3, 2023 at $40.12.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The company products include Oxtellar XR, Trokendi XR, SPN-812, and others.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App